PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Polyphor has won the Swiss Technology Award in the Innovation Leader category. The biopharmaceutical company from the Basel region has a portfolio that includes innovative antibiotics.
At a ceremony in Basel, the biopharmaceutical company received its prize in the Innovation Leader category, which honours technology-based innovations and developments. Polyphor’s innovation is its proprietary macrocycle platform. The company used it for the development of “a new class of antibiotics against Gram-negative bacteria with a novel mode of action”, explains the statement.
"We are very honored to receive this prestigious award as it validates the importance of our innovation and the perseverance of our whole team in developing new treatments for patients so much in need," commented Daniel Obrecht, Chief Scientific Officer and Co-Founder of Polyphor.
Using the macrocycle platform, Polyphor developed its lead drug candidate Murepavadin, an antibiotic that targets resistant infections and is currently undergoing Phase III clinical trials. Another candidate developed with the macrocycle platform is Balixafortide, which is aimed at treating breast cancer and is nearing the end of clinical development.
"It has been a lengthy and arduous journey, from the development of the proprietary macrocycle-based discovery platform, which is the source of the discovery and development of our product pipeline, to the pivotal trial of our lead candidate Murepavadin and we hope that our drugs will soon make a significant and transformational contribution toward the improvement of public health," added Obrecht.
This year, the 30th Swiss Technology Award was held.